Turnkey Sterile Medical Device Packaging Solutions


Publish Date:

Last Modified Date:

Category: Product sheet

Tags: Tags:

medical device packaging

Turnkey Sterile Medical Device Packaging and Sterilization Solutions

Our turnkey packaging services are ideal for sterile surgical and procedure kits where multiple components are packed together and lot control and traceability are of the highest importance. Our packaging processes are validated and we have a long track record of exceptional on-time delivery. We specialize in medical device contract manufacturing of both small and medium volume products.

We offer a full range of medical device outsourcing solutions includingmedical device package design and validation, managing sterilization from protocol development, publishing final test results, and managing the ongoing sterilization process, including laboratory testing. We offer in-house medical device EtO sterilization as well as “single release” where no validation is required.

In-House Thermoforming

We provide better quality medical device contract packaging services because we control the thermoforming process of the packaging trays. We pride ourselves on our unparalleled ability to work with heavy gauge and other difficult materials such as polycarbonate. Our thermoformed packaging capabilities include post-forming fabrication to manufacturing thermoformed packaging with vents, handles, locking tabs, and welded internal components. We also provide customized trays to support specialized lyophilization processes.

Broad Array of Formats

J-Pac Medical performs cleanroom assembly and packaging sterile devices in eleven class 7 and 8 clean rooms. Formats include Form Fill SealTray/LidBags, and Foil Pouches. We also specialize in gas flushing and dry room packaging.

Case Study: Packaging Design Optimization

The Challenge

A Cardiovascular Device Company came to J-Pac Medical with a request to establish a contract packaging capability in the United States. The existing packaging flow had been established in Europe, as was the package design.

Our Solution

As part of the overall transfer, J-Pac proposed a total redesign of this existing package to reduce the overall footprint, as well as downgauge all packaging materials.

The Results

In addition to reducing the overall footprint and down-gauging packaging materials, our redesigned package also enabled a 40% increase in Eto Sterilization throughput. Freight gains were also realized.


medical device packaging

Using Pre-Validated Medical Device Packaging to Speed Time to Market


Publish Date:

Last Modified Date:

Category: White paper

Tags: Tags:

There is a lot of excitement in the medical device packaging industry about pre-validated packaging.

Using pre-validated packaging may reduce time to market and minimize package development and validation expenses. However, international standards defining medical device validation requirements are complex, involving materials selection, design qualification, process validation, and design controls. Pre-validated packaging may not comply with all the requirements depending on the specific device involved. Nevertheless, pre-validated packaging can be a helpful strategy if adequately implemented by the device packager within the framework of these standards. This paper aims to clarify when pre-validated packaging makes sense and how its cost and lead time compare to a custom-designed package.

Packaging Standards for Terminally Sterilized Devices

Sterile packaging systems need to ensure the sterility of their contents until they are opened for use. The sterile barrier system (SBS) must also be designed to ensure aseptic presentation at the point of use. ISO 11607 (part 1 and part 2) is the global standard governing packaging for terminally sterilized medical devices. ISO 11607-1 defines requirements for SBS materials selection, and their design and testing. ISO Sterile packaging systems need to ensure the sterility of their contents from shipping through the point of use. The sterile barrier system (SBS) must allow aseptic presentation into the sterile field. ISO 11607 (part 1 and part 2) is the global standard governing packaging for terminally sterilized medical devices. Part 1 of the standard defines requirements for SBS materials selection and their design and testing. Part 2 defines manufacturing critical process validation requirements for forming, sealing, and assembly processes.

Key Definitions

ISO 11607 provides precise terminology used for medical device and healthcare packaging.

Sterile Barrier System (SBS): The minimum package that minimizes the risk of ingress of microorganisms and allows aseptic presentation of the sterile contents at the point of use. For example, a thermoformed tray with a Tyvek lid can be an SBS. Header bags and Chevron pouches are standard sterile barrier systems.

Protective Packaging: The configuration of materials designed to prevent damage to the sterile barrier system and its contents from the time of their assembly until the point of use. These include shelf cartons and shipping boxes.

Preformed Sterile Barrier System: A sterile barrier system that is supplied partially assembled for filling and final closure or sealing. Examples of these include porous and nonporous chevron pouches, header and patch bags. These are typically purchased from packaging suppliers partially assembled and used during final packaging by making a final closure seal. A thermoformed tray also falls within this definition.

Packaging System: The combination of the sterile barrier system and protective packaging. Both work in tandem to protect the product and the sterile barrier.

protective packaging system diagram

How is Sterile Packaging Validated?

ISO 11607 and ISO 11135 define the requirements for validating terminally sterilized medical device packaging.

  1. Design Qualification. Packaging materials must be selected and documented within a quality system based on the requirements of the device and sterilization method used. These include the adequacy of the microbial barrier, biocompatibility and toxicity attributes, sterilization effects, sealing effectiveness, compatibility of the device and SBS materials that contact each other, and compatibility with labeling.
  2. Stability Tests. The sterile barrier seals must be proven to maintain sterility over time. Validation involves a post-sterilization stability study. The sealing and sterilization parameters for this test must be under worst-case conditions. The FDA allows accelerated stability testing if real-time testing occurs in parallel.
  3. Sealing Validation. The sterile barrier system’s sealing process must be validated. This requires a critical manufacturing process validation, which includes an IQ, OQ, and PQ on the sealing equipment performed at the manufacturing location.
  4. Transit Simulation. Transit testing must reflect how the product will be shipped
  5. Sterilization Validation. Sterilization results in a 10-6  probability of any infecting microbes surviving the sterilization process.

What is pre-validated packaging?

A pre-validated package eliminates the need for design qualification (1), stability testing (2), and sealing validation (3). It does not negate the need for transit testing because each packaged product may impact the seal differently. Likewise, sterilization validation is still required because it is unique to the product – not the package.

When is pre-validated packaging preferred?

Pre-validated sterile packaging is a novel concept that, if properly executed, can help MDM’s reduce

Pre-Validated Packaging

  • High probability package will change
  • A clinical trial is the next step

Custom Packaging

  • Low probability package will change
  • Commercial launch is the next step

What sterilization validation methods are typical?

The available sterilization validation methods are “full validation” and “single batch release.” A full validation validates the cycle parameters and the specific equipment. The single batch release verifies each lot separately. Three single batch releases performed in twelve months may equate to a full validation after a retrospective analysis.

Batch Release Sterilization

  • High probability package will change
  • Commercial launch in <16 weeks
  • Higher Cost

Sterilization Validation

  • Low probability package will change
  • Commercial launch >16 weeks

Time and cost savings

Typical project plan for pre-validated packaging


Pre-validated sterile packaging is a novel concept that, if properly executed, can help MDMs reduce expenses and improve time to market. However, the ISO 11607 standard (Parts 1 and 2) is complex and cites three critical components of a “validated” packaging system. (A) The design and development of the packaging system include material selection, design, and packaging qualification testing, (B) qualifying or validating or providing proof of the stability of the SBS materials and seals, and (C) sealing process validation.

The MDM’s unique devices, sterilization cycle, distribution environment, and manufacturing processes often require pre-validated packaging solutions to undergo additional qualification and validation testing to satisfy regulatory requirements. MDMs should ask specific questions to understand how pre-validated packaging meets these requirements and identify any further testing that may be required. Finally, MDMs must ensure that all validation data is maintained in their design history files, as they are ultimately responsible.

Additional Resources

ISO 11607-1:2006/(R) 2010 Packaging for terminally sterilized medical devices—Part 1: Requirements for materials, sterile barrier systems, and packaging systems and ISO 11607-1: 2006/A1: 2014 Packaging for terminally sterilized medical devices – Part 1: Requirements for materials, sterile barrier systems, and packaging, Amendment 1

ISO 11607-2:2006/(R) 2010 Packaging for terminally sterilized medical devices—Part 2: Validation requirements for forming, sealing and assembly processes and ISO 11607-2: 2006/A1: 2014 Packaging for terminally sterilized medical devices – Part 2: Validation requirements for forming, sealing, and assembly processes, Amendment 1

ANSI/AAMI/ISO TIR16775: 2014, Technical Information Report, Packaging for terminally sterilized medical devices-Guidance on the application of ISO 11607-1 and ISO 11607-2.

Establishing Shelf Life of Medical Devices


Publish Date:

Last Modified Date:

Category: White paper

Tags: Tags:

Custom single use medical device tray

Determining a medical device’s shelf life can be one of the more challenging aspects of a new device development program.

It’s also one of the most overlooked.

The process for establishing medical device shelf life is quite complex and involves rigorous testing. And in our view, there’s a specific strategy for developing these tests that sets medical device manufacturers up for long-term success.

In this white paper, we’ll cover:

  • How shelf life is defined and the role a risk assessment plays in establishing shelf life
  • How the ISO 11607-1 and -2 standards contribute to establishing shelf life
  • Suggested shelf life testing procedures and testing requirements
  • Our view of the ideal shelf life testing strategy

With this resource, your new device development team can reduce the testing timeline and oversee a smoother, faster product launch.

Get the guide

Validating Medical Device Assembly, Packaging, & Sterilization


Publish Date:

Last Modified Date:

Category: White paper

Tags: Tags: ,

Prevalidated sterile package with urethane insert

According to the World Health Organization (WHO), healthcare-associated infections (HAIs) are the most frequent adverse event in the delivery of healthcare services worldwide. Ensuring the sterility of medical devices is a critical step in the overall effort to reduce the rate of infections in hospitals and other healthcare settings.

Medical device packaging and sterilization validation are required for FDA 510(k) submissions yet are often causes of delay. Sterile packaging validation is a vastly misunderstood topic in its own right but becomes even more complicated when considering it involves the additional coordination of manufacturing, product shelf life, and sterilization validations all under a complicated array of regulations. This white paper explains how these validation requirements must be coordinated for medical device manufacturers to get their single-use medical devices to market faster.

Key Regulations

Medical device OEMs typically work with three separate entities for the back-end stages of product realization: medical device outsourcing companies, testing labs, and sterilization companies. It is common for these entities to focus on their particular expertise without helping the OEM navigate the process as a whole.

The best way to think about the market launch requirements of sterilized, single-use medical devices is to think in terms of how these requirements work together.

1. Package Design

Package design is regulated by ISO 11607 (Part 1 and Part 2), and these standards are universally required by the FDA and the EU Medical Device Regulations. ISO 11607 is one of the most misunderstood standards in device development, requiring the execution of more than 25 specifications, protocols, and test reports.

protective packaging system diagram

The regulations require that sterile packaging be treated holistically as a Sterile Packaging System. A sterile packaging system is much more than a sterile barrier package; it is the combination of the sterile barrier system and external protective packaging required to deliver the device from manufacturing through sterilization, storage, distribution, and aseptic delivery to the sterile field. This requires a significant amount of design activities, verification, and validation. Most importantly, it requires a complete understanding of the stresses the package will endure throughout the distribution cycle.

ISO 11607-1 defines requirements for sterile barrier system materials selection and their design and testing. ISO 11607-2 defines manufacturing packaging process validation requirements for forming, sealing, and assembly processes. Too frequently, medical device manufacturers do not include assembly process validation as part of the equation.

Some of the critical steps of this standard include:

  • Developing packaging system requirements that specify the customer’s design needs for the sterile barrier and the protective packaging systemMedical device manufacturers must obtain customer feedback on the package ease-ofuse and gain a solid understanding of the storage, transportation, and shelf life requirements of the device. Other considerations include the requirements for the microbial barrier and evaluating possible interactions with the sterilization method on both the sterile barrier as well as the device itself.
  • Designing a sterile barrier . Examples of these include porous and nonporous pouches, header, patch bags, and thermoformed trays. The packaging solution is a direct result of the system requirements.
  • Designing protective packaging to ensure the device can survive transportation stresses from the point of manufacture to the customer. One of the most common causes of packaging failures is not considering how products are shipped to customers. For example, palletized products from the manufacturer must be tested to ensure they can be delivered through sterilization, but further testing is required if those pallets are broken down and the product is shipped to customers through common carriers. Having a box thrown into a UPS truck is not the same as shipping a skid from the manufacturer. One of the most common mistakes we see is not considering consolidated shipping configurations that are used for sterilization. Orthopedic implants, in particular, generate significant stresses on packaging and are highly sensitive to shipping configurations.
  • Package prototyping is recommended to ensure the final package will meet the needs of the customer and will be manufacturable and optimized for final assembly of the device. Selecting a contract manufacturer with internal thermoforming and a broad array of packaging technologies can provide companies with a realistic sample of the final package much faster than having to coordinate multiple suppliers.
  • Package verification testing is a critical step and is often overlooked, which increases the chance that the package fails the final transit test. In this step, the final version of the product is packaged and undergoes preliminary package testing to ensure it has a high probability of passing the final transit testing. Some labs report up to 30% of their medical device packages fail the ASTM or ISTA transit tests. A preliminary transit test greatly reduces this risk. Typical sterile package verification tests include peel testing and bubble leak testing. These tests must be validated in advance.
  • A sterile presentation test must be conducted with actual end-users to ensure the medical device can be aseptically presented. Scrub nurse and doctor interaction with the package is critical. Some packages can be designed to deliver the device to the sterile field by allowing the device to gently “fall” out of the package onto a sterile table. Other devices require the product to be held over the sterile field while the scrub nurse manually removes the device from the package. Each of these scenarios impacts the design of the package regarding ease of opening and, for thermoformed trays, how the package is designed to be held with one hand while peeling the lid with the other.

2. Validation of Forming, Sealing, and Package Assembly

The process used to assemble the package and seal the sterile barrier must be validated. Key steps include:

  • Developing a sampling plan that applies to the process being validated, based on a statistically valid rationale. ISO 2859-1 or ISO 186 are common references.
  • Using a validated test method and defining the criteria for acceptance.
  • Tooling design and fabrication. IQ (Installation Qualification) for forming and sealing equipment.
  • OQ (Operational Qualification) of the sealing process. This involves challenging the sealing process parameters to create windows of variability that the process must maintain to provide an acceptable seal. It is imperative that products produced for subsequent sterilization and transit testing be produced at OQ-Low to simulate worst-case manufacturing conditions. This is often overlooked and can yield compromised packaging during ongoing production when sealing parameters drift to the low end of their specification. This requirement ensures that a seal made under the worst-case process variation will stay intact.
  • PQ (Process Qualification). This step involves producing product under realworld manufacturing conditions including multiple shifts and operators. The fastest path of validation involves using OQ-Low to validate post-sterilization transit and seal stability testing and PQ for final sterilization validation

3. Manufacturing Process Validation

Validating the sealing process is just one element of the manufacturing validation, which must include all the cleanroom assembly steps to produce the device. A separate IQ, OQ, and PQ must be performed for the assembly process prior to sterilization validation. Conducting the production and assembly process validation in conjunction with package validation saves significant time.

4. Worst-Case Sterilization

Sterilization can put significant stresses on a package and also can impact the shelf life of the device. To reduce the risk of failure the medical device package must be exposed to worst-case sterilization prior to transit testing. “Worst-case” needs to be justified. A double (2X) sterilization is often used to simulate worst-case. A 2X sterilization cycle may occur when there is a sterilization cycle that needs to be aborted due to mechanical failure, or there is a need to re-label a previously sterilized product. Your contract manufacturer should coordinate a discussion with the sterilizer to determine the best assumptions.

5. Transit Testing

Transit testing has two objectives. The first is to evaluate if the product and package interaction during shipping will compromise either the sterile barrier or the product itself. The second is to determine if sterilization will impact the sterile barrier irrespective of the product interaction.

An ISTA or ASTM transit test should be selected that best reflects the actual transportation and storage environment that the package will experience. There are a variety of possible distribution cycles for transit simulation including air and motor freight. Test conditions include atmospheric conditioning (e.g., humidity, temperature), compression, vibration, and shock. Testing for both palletized movement and individual shipper handling are crucial considerations.

ISO 11607 requires proper documentation and a rationale for the use of a particular test along with detailed conditions under which the sterile barrier must be maintained.

6. Seal Testing

Always conduct seal tests with empty packages. This allows the sterilization effect on the package seal to be independently evaluated. There are many reported cases where package design has been changed unnecessarily because there was not independent testing of the seal. In essence, if the seal is not tested independently and the transit test fails, the customer will not know if the failure was caused by the seal design or the impact of the product. Costs are increased because tests must be repeated, and product is wasted. Similarly, testing full packages increases the volume of product that needs to be manufactured for the test.

Seal tests can involve several ASTM test methods with the most popular being the bubble leak test, visual seal inspection, and peel strength testing. These tests are performed after both accelerated and real-time stability testing. The FDA will accept accelerated shelf life testing as long as real-time testing is completed in parallel. The desired shelf life dramatically impacts the cost of the test due to the sample size and test time required.

Accelerated shelf life testing allows the product to be launched more quickly and can be critical to supporting clinical trials. A one-year shelf life label can be accomplished in just 46 days of accelerated aging; this is adequate for clinical testing. Two types of stability tests must occur: tests on the seal design and tests to ensure the packaged device does not negatively impact the seal. The medical device must also be tested to ensure its functionality is acceptable for each point of shelf life testing (1 yr., 2 yr., etc.).

7. Sterilization Validation

There are two main methods of validating medical device sterilization.

First is validating the desired load size for ongoing production. This method requires that the planned batch size be validated as a group. For example, a four-pallet Eto chamber process can be validated with four pallets of packaged product or a smaller amount of packaged product with dunnage that simulates the density of the larger load. This can be an impractical method for new product launches because it often requires more product to be produced than needed for initial market launch.

The second popular method is “single lot release.” This is accomplished by sterilizing three separate smaller lots of product and then performing a retrospective study to create a validated sterilization process. All three lots must be processed within one year. The single-lot release is a sterilization verification method — not a validation method — because each lot is tested to verify its sterility. This is often more expensive than validating a larger load but is often the most practical approach.

Sterilization validation should use manufactured product out of PQ so that it represents product produced under a validated manufacturing process. So, while package transit testing should use OQ-low to ensure the package protects under worst-case conditions, product from the sterilization validation should be validated using PQ production. This way customers can use the product undergoing sterilization validation.

Timing of the Complete Validation Process

Timing and costs can vary greatly depending on the medical device validation strategy deployed as well as how coordinated the individual processes are managed. Your medical device outsourcing partner should provide a detailed schedule of timing and costs for various scenarios. This timing must also be integrated into the higher-level product development plan. It is very typical for customers to be surprised by the length of this process which often delays 510(k) submissions.

Package Design (#1): 13 Weeks

Sealing and Manufacturing Process Dev. (#2/3) 16 Weeks

Transit Testing and Seal Testing (#4/5/6) 13 Weeks

Sterilization Validation (Assume Lot #1) 8 Weeks

These are typical lead times, but they can be significantly reduced by selecting an outsourcing partner well versed in all aspects of the process as well as having vertically integrated packaging and manufacturing processes.


The requirements for validating the back-end processes for medical device package designmanufacturingsterilization and shelf life of a sterile medical device is often misunderstood. Errors and oversights can result in failed validation tests and longer-term sterile barrier reliability. It can take nearly a year to get a validated sterile package to market, and many medical device manufacturers fail to plan for this time and expense. While there are regulations that govern package design and validation, additional regulations for manufacturingsterilization, and shelf life validation must also be coordinated to reduce lead-time, improve quality, and reduce costs. Using an integrated approach to treat all these processes as a system, achieves a faster and less expensive approach. OEMs should ensure that their medical device contract manufacturing partners are well versed in this area and can offer comprehensive schedules and cost estimates that reflect the entire process.

Medical Device Packaging Design Optimization


Publish Date:

Last Modified Date:

Category: Case study

Tags: Tags:

The Challenge

A Cardiovascular Device Company came to J-Pac Medical with a request to establish a medical device contract packaging capability in the United States for an existing packaging flow had been established in Europe, as was the package design.

Our Solutions

As part of the overall transfer, J-Pac proposed a package design and validation to reduce the overall footprint, as well as downgauge all packaging materials.

The Results

In addition to reducing the overall footprint and down-gauging packaging materials, our redesigned package also enabled a 40% increase in Eto Sterilization throughput. Freight gains were also realized. J-Pac also provided medical device cleanroom assembly as part of its medical device outsourcing services.